# US 2003/0069256 A1 · Use of isogenic human cancer cells for high-throughput screening and drug discovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069256 A1
- Document ID: US20030069256A1
- Status: Published application
- Kind: A1
- Application number: 09/961,407
- Filed: 2001-09-25
- Published: 2003-04-10
- Earliest claimed: 2001-09-25
- Inventors: Christopher J. Torrance; Bert Vogel Stein; Kenneth W. Kinzler
- Web page: https://patentgrep.com/patent/US20030069256A1

## CPC

- C07D 257/04: Five-membered rings
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 19/16: Purine radicals
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5023: {on expression patterns}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A strategy for drug-screening is based on cells that are isogenic except for a gene of interest. Each cell can be tranfected with a vector that encodes a different fluorescent protein that can be differentially detected to monitor cell growth. Co-culture of both cells allows facile screening for compounds with selective toxicity towards a gene of interest. The drug screening is broadly applicable for mining therapeutic agents targeted to specific genetic alterations responsible for cancer development.

## Claims

### Claim 1

A pair of cells comprising:
a first cell; and
a second cell,
wherein the first cell and the second cell are isogenic but for:
a gene of interest and a gene encoding a fluorescent protein;
wherein the first cell comprises a gene that encodes a first fluorescent protein having a first absorption spectrum and a first emission spectrum;
wherein the second cell comprises a gene that encodes a second fluorescent protein having a second absorption spectrum and a second emission spectrum; and
wherein either:
the first and second absorption spectra are not identical; and/or
the first and second emission spectra are not identical.

### Claim 2 (depends on 1)

The pair of cells of claim 1 wherein the first and second absorption spectra are not identical and the first and second emission spectra are not identical.

### Claim 3 (depends on 1)

The pair of cells of claim 1 wherein the cells are contained within the same undivided container.

### Claim 4 (depends on 1)

The pair of cells of claim 1 wherein the first cell is homozygously wild-type for the gene of interest and wherein the second cell is homozygously mutant for the gene of interest.

### Claim 5 (depends on 1)

The pair of cells of claim 1 wherein the gene of interest in the second cell is homozygously deleted.

### Claim 6 (depends on 1)

The pair of cells of claim 1 wherein the first cell comprises two wild-type alleles of the gene of interest and wherein the second cell comprises a wild-type allele and a mutant allele of the gene of interest, wherein the mutant allele is dominant.

### Claim 7 (depends on 1)

The pair of cells of claim 1 wherein the gene of interest is an oncogene and the first cell is homozygous for a mutant allele of the oncogene and wherein the second cell comprises a homozygous deletion of the mutant oncogene.

### Claim 8 (depends on 1)

The pair of cells of claim 1 wherein the first cell expresses the gene of interest and wherein the second cell does not express the gene of interest.

### Claim 9 (depends on 1)

The pair of cells of claim 1 wherein the first cell comprises a wild-type allele and a mutant allele of the gene of interest and the second cell is hemizygous for the wild-type allele of the gene of interest.

### Claim 10 (depends on 1)

The pair of cells of claim 1 wherein the first cell expresses a protein encoded by the gene of interest and wherein the second cell does not express a protein encoded by the gene of interest.

### Claim 11 (depends on 1)

The pair of cells of claim 1 wherein the first and second cells are mammalian cells.

### Claim 12 (depends on 1)

The pair of cells of claim 1 wherein the first and second cells are human cells.

### Claim 13 (depends on 1)

The pair of cells of claim 1 wherein the cells are cancer cells.

### Claim 14 (depends on 13)

The pair of cells of claim 13 wherein the cancer cells are selected from the group consisting of colon tumor cells and breast tumor cells.

### Claim 15 (depends on 1)

The pair of cells of claim 1 wherein the cells are HCT116 cells.

### Claim 16 (depends on 1)

The pair of cells of claim 1 wherein the cells are DLD-1 cells.

### Claim 17 (depends on 1)

The pair of cells of claim 1 wherein the first and second fluorescent proteins are selected from the group consisting of green fluorescent protein, red fluorescent protein, blue fluorescent protein, yellow fluorescent protein, and cyan fluorescent protein.

### Claim 18 (depends on 1)

The pair of cells of claim 1 wherein the gene of interest is Ras and wherein the Ras genotype of the first cell is c-Ki-RasWT/mutant and wherein the Ras genotype of the second cell is c-Ki RasWT/null.

### Claim 19

A pair of cells comprising:
a first cell wherein the Ras genotype of the first cell is c-Ki-RasWT/mutant and wherein the first cell comprises a first gene that encodes a first fluorescent protein having a first absorption spectrum and a first emisson spectrum; and
a second cell wherein the Ras genotype of the second cell is c-Ki-RasWT/null and wherein the second cell comprises a second gene that encodes a second fluorescent protein having a second absorption spectrum that is not identical to the first absorption spectrum and a second emission spectrum that is not identical to the first emission spectrum, wherein the first and second cells are isogenic but for the Ras gene and the gene encoding a fluorescent protein.

### Claim 20 (depends on 19)

The pair of cells of claim 19 wherein the first fluorescent protein is blue fluorescent protein and the second fluorescent protein is yellow fluorescent protein.

### Claim 21

A method of making a pair of cells, comprising the steps of:
genetically modifying a first cell to yield a second cell that is isogenic with the first cell but for a single gene of interest;
transfecting the first cell with a first gene that encodes a first fluorescent protein having a first absorption spectrum and a first emission spectrum; and
transfecting the second cell with a second gene that encodes a second fluorescent protein having a second absorption spectrum and a second emission spectrum, wherein either the first and second absorption spectra are not identical and/or the first and second emission spectra are not identical.

### Claim 22 (depends on 21)

The method of claim 21 wherein the first and second absorption spectra are not identical and wherein the first and second emission spectra are not identical.

### Claim 23 (depends on 21)

The method of claim 21 wherein the first and second cells are mammalian cells.

### Claim 24 (depends on 21)

The method of claim 21 wherein the first and second cells are human cells.

### Claim 25 (depends on 24)

The method of claim 24 wherein the human cells are human cancer cells.

### Claim 26 (depends on 25)

The method of claim 25 wherein the human cancer cells are selected from the group consisting of colon tumor cells and breast tumor cells.

### Claim 27 (depends on 21)

The method of claim 21 wherein the first and second cells are HCT 116 cells.

### Claim 28 (depends on 21)

The method of claim 21 wherein the first and second cells are DLD-1 cells.

### Claim 29 (depends on 21)

The method of claim 21 wherein the Ras genotype of the first cell is c-Ki-RasWT/mutant and wherein the Ras genotype of the second cell is c-Ki-RasWT/null.

### Claim 30

A method of identifying a test compound as selectively affecting a gene of interest or its expression products or downstream genes or proteins in its pathway comprising the steps of:
culturing a first and second cell, wherein the first and second cells are isogenic but for a gene of interest and a gene encoding a fluorescent protein, wherein the first cell comprises a first gene that encodes a first fluorescent protein having a first absorption spectrum and a first emission spectrum, and wherein the second cell comprises a second gene that encodes a second fluorescent protein having a second absorption spectrum and a second emission spectrum, wherein either the first and second absorption spectra are not identical and/or the first and second emission spectra are not identical;
contacting the first and second cells with a test compound; and
identifying the test compound as selectively affecting the gene of interest or its expression products or downstream genes or proteins in its pathway if the growth rate of the first cell is altered with respect to the growth rate of the second cell.

### Claim 31 (depends on 30)

The method of claim 30 wherein the first and second cells are co-cultured.

### Claim 32 (depends on 30)

The method of claim 30 wherein an equal number of the first and second cells are cultured.

### Claim 33 (depends on 30)

The method of claim 30, wherein the first and second absorption spectra are not identical and wherein the first and second emission spectra are not identical.

### Claim 34 (depends on 30)

The method of claim 30 wherein the fluorescent proteins are detected using fluorescence microscopy to assess growth rate.

### Claim 35 (depends on 30)

The method of claim 30 wherein the fluorescent proteins are detected using high-throughput fluorescence spectroscopy to assess growth rate.

### Claim 36 (depends on 30)

The method of claim 30 wherein the first cell is homozygously wild-type for the gene of interest and wherein the second cell is homozygously mutant for the gene of interest.

### Claim 37 (depends on 30)

The method of claim 30 wherein the gene of interest in the second cell is homozygously deleted.

### Claim 38 (depends on 30)

The method of claim 30 wherein the first cell comprises two wild-type alleles of the gene of interest and wherein the gene of interest in the second cell comprises a wild-type allele and a mutant allele of the gene of interest, wherein the mutant allele is dominant.

### Claim 39 (depends on 30)

The method of claim 30 wherein the first cell is homozygous for a mutant oncogene and wherein the second cell comprises a homozygous deletion of the mutant oncogene.

### Claim 40 (depends on 30)

The method of claim 30 wherein the first cell expresses the gene of interest and wherein the second cell does not express the gene of interest.

### Claim 41 (depends on 30)

The method of claim 30 wherein the first cell comprises a wild-type allele and a mutant allele of the gene of interest and wherein the second cell is hemizygous for a wild-type allele of the gene of interest.

### Claim 42 (depends on 30)

The method of claim 30 wherein the first cell expresses a mutant protein encoded by the gene of interest and wherein the second cell does not express a protein encoded by the gene of interest.

### Claim 43 (depends on 30)

The method of claim 30 wherein the first and second cells are mammalian cells.

### Claim 44 (depends on 30)

The method of claim 30 wherein the first and second cells are human cells.

### Claim 45 (depends on 30)

The method of claim 30 wherein the cells are cancer cells.

### Claim 46 (depends on 45)

The method of claim 45 wherein the cancer cells are selected from the group consisting of colon tumor cells and breast tumor cells.

### Claim 47 (depends on 30)

The method of claim 30 wherein the first and second cells are HCT116 cells.

### Claim 48 (depends on 30)

The method of claim 30 wherein the first and second cells are DLD-1 cells.

### Claim 49 (depends on 30)

The method of claim 30 wherein the first and second fluorescent protein are selected from the group consisting of green fluorescent protein, red fluorescent protein, blue fluorescent protein, yellow fluorescent protein, and cyan fluorescent protein.

### Claim 50

A method of identifying a test compound as selectively affecting a Ras gene, Ras protein, or downstream gene or protein in its pathway in cells comprising:
contacting a test compound with a co-culture of an essentially equal number of a first and a second cell that are isogenic but for their Ras genes and a gene encoding a fluorescent protein, wherein the Ras genotype of the first cell is c-Ki-RasWT/mutant and wherein the first cell comprises a first gene encoding a first fluorescent protein having a first absorption spectrum and a first emisson spectrum and wherein the Ras genotype of the second cell is c-Ki-RasWT/null and wherein the second cell comprises a second gene encoding a second fluorescent protein having a second absorption spectrum that is not identical to the first absorption spectrum and a second emission spectrum that is not identical to the first emission spectrum; and
identifying the test compound as selectively affecting the Ras gene, Ras protein, or downstream gene or protein in the pathway if the growth rate of the first cell is altered with respect to the growth rate of the second cell.

### Claim 51 (depends on 50)

The method of claim 50 wherein the first fluorescent protein is blue fluorescent protein and wherein the second fluorescent protein is yellow fluorescent protein.

### Claim 52

A composition comprising at least 90% of a compound having a formula selected from the group consisting of:
4

### Claim 52

A method of treating cancer comprising:
administering to a patient in need thereof a therapeutically effective amount of a compound having a formula selected from the group consisting of:
7
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically appropriate carrier.

### Claim 53

A pharmaceutical composition comprising a compound with a formula selected from the group consisting of:
5
or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and a pharmaceutically appropriate carrier.

### Claim 54

A cytotoxic composition comprising a compound having a formula:
6
or a pharmaceutically acceptable salt, solvate, or prodrug thereof; and
a pharmaceutically appropriate carrier.
